Literature DB >> 36157634

Malignant transformation of biliary adenofibroma combined with benign lymphadenopathy mimicking advanced liver carcinoma: A case report.

Shao-Cheng Wang1, Yan-Yan Chen1, Fei Cheng2, Hai-Yong Wang1, Fu-Sheng Wu1, Li-Song Teng3.   

Abstract

BACKGROUND: Biliary adenofibromas (BAFs) are rare primary hepatic neoplasms, some of which can potentially undergo malignant transformation. Here, we describe a rare case of malignant transformation of BAF. CASE
SUMMARY: A 51-year-old female was referred to our hospital with epigastric pain. Computed tomography showed a solitary liver mass combined with the enlargement of multiple mediastinal and cervical lymph nodes, clinically mimicking a liver carcinoma with extensive lymph node metastasis. However, core needle biopsy suggested BAF with malignant transformation. Finally, the patient underwent curative resection of the neoplasm and was recurrence-free for 12 mo.
CONCLUSION: Our case serves as an example of a rare manifestation of BAF. Our report and the previously published experience, reinforce that curative resection should be considered the primary treatment for BAFs with malignant transformation, leading to a favorable prognosis. ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Biliary adenofibroma; Case report; Lymphadenopathy; Malignant transformation; Surgery

Year:  2022        PMID: 36157634      PMCID: PMC9477047          DOI: 10.12998/wjcc.v10.i25.9104

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.534


Core Tip: Biliary adenofibromas (BAFs) are rare primary hepatic neoplasms, some of which have potential of malignant transformation. Here we describe a rare case of malignant transformation of BAF presented with epigastric pain, whose imaging showed solitary liver mass combined with enlargement of multiple mediastinal and cervical lymph nodes, clinically mimicking a liver carcinoma with extensive lymph node metastasis. The patient was treated with curative resection of the neoplasm and has been recurrence-free for 12 mo. Our case is a rare manifestation of BAF and our experience supported that curative resection should be considered the primary treatment for BAFs with malignant transformation, which leads to a favorable prognosis.

INTRODUCTION

Biliary adenofibromas (BAFs) are rare primary neoplasms of the liver first described by Tsui et al[1] in 1993, most of which are benign biliary cystic tumors[2,3]. Although BAFs are benign tumor with indolent biological behavior, some BAFs have the potential to undergo malignant transformation, leading to transition to invasive carcinoma. To date, few cases of BAFs with malignant features have been reported[4,5]. In the present report, we describe an extremely rare case of malignant transformation of BAF combined with benign lymphadenopathy, which clinically mimicked liver carcinoma with extensive lymph node metastasis. The patient underwent a complete surgical resection of the disease. Meanwhile, we provide a brief review of literature concerning malignant transformation of BAFs.

CASE PRESENTATION

Chief complaints

A 51-year-old female with a 2-mo history of epigastric pain.

History of present illness

The pain was barely noticeable initially and steadily worsened thereafter. On the initial evaluation, she had loss of appetite, a 5 kg weight loss, and denied nausea, vomiting, or jaundice. The patient had periodic episodes of fever ranging from 37.5°C to 38.6°C for about a week.

History of past illness

The patient had laparoscopic cholecystectomy 6 years ago. Other medical, surgical, psychosocial, and family histories were non-contributory.

Personal and family history

The patient denied any family history.

Physical examination

Physical examination revealed mild epigastric tenderness that was otherwise unremarkable.

Laboratory examinations

The patient had an elevated C-reactive protein (CRP) of 75.1 mg/L, while the white blood cell count was within the normal range. The tumor markers alpha-fetoprotein, carcinoembryonic antigen, and cancer antigen 19-9 were within normal ranges. Liver function was normal, and serology was negative for hepatitis B and hepatitis C virus infections.

Imaging examinations

The patient was referred to an oncologic surgeon. Contrast abdominal computed tomography (CT), and subsequent magnetic resonance imaging showed a 9.2 cm × 5.9 cm solitary mass in hepatic segments VII and VIII, which was unevenly enhanced during the arterial phase and washed out during the venous phase (Figure 1). Additionally, pulmonary CT showed multiple enlarged merging mediastinal and cervical lymph nodes (Figure 2A). The leading diagnosis based on imaging was malignant liver carcinoma, possibly hepatocellular carcinoma or intrahepatic cholangiocarcinoma, with extensive lymph node metastasis. To exclude possible distant metastasis, positron emission tomography/ computed tomography was conducted, which showed uneven fluorodeoxyglucose (FDG) uptake (maximum SUV 6.7) in the liver mass, elevated FDG uptake (maximum SUV 1.9) in multiple mediastinal and cervical lymph nodes (Figure 2B and C), and no suspicious FDG elevation in the lung, brain, or pelvic cavity.
Figure 1

Computed tomography, magnetic resonance imaging and positron emission tomography/computed tomography images of liver mass and mediastinal lymphadenopathy. A: Abdominal contrast computed tomography, venous phase; B-D: Representative images from the MRI study (B: Venous phase; C: Sagittal venous phase; D: Diffusion weighted).

Figure 2

computed tomography images. A: Pulmonary computed tomography, mediastinal window; B: Representative positron emission tomography/computed tomography images, left, mediastinum, right, abdominal.

Computed tomography, magnetic resonance imaging and positron emission tomography/computed tomography images of liver mass and mediastinal lymphadenopathy. A: Abdominal contrast computed tomography, venous phase; B-D: Representative images from the MRI study (B: Venous phase; C: Sagittal venous phase; D: Diffusion weighted). computed tomography images. A: Pulmonary computed tomography, mediastinal window; B: Representative positron emission tomography/computed tomography images, left, mediastinum, right, abdominal.

FINAL DIAGNOSIS

A core needle biopsy was suggested to guide systemic treatment. Unexpectedly, the pathological finding for the biopsy suggested an epithelial neoplasm with a tubuloglandular structure. The epithelial cells immunohistochemically stained positive for cytokeratin (CK) 7 and CK19 but negative for glypican-3, p53, and hepatocyte-specific antigen, implying a biliary origin. The ki-67 index was approximately 5%. The morphology and molecular pathology were compatible with adenofibroma with a malignant transformation. The patient underwent a cervical lymph node excisional biopsy to exclude distant lymph node metastasis. Three swollen lymph nodes were resected, which were negative for cancerous components.

TREATMENT

Our team decided to perform surgery on this patient based on the current knowledge of biliary adenofibroma with malignant transformation. Complete local resection of the hepatic lesion and resection of multiple merged lymph nodes in the anterior-inferior mediastinum were performed (the macroscopic view is presented in Figure 3). In detail, under general anesthesia, open atypical hepatectomy was done by Cavitron Ultrasonic Surgical Aspirator to remove the tumor with a margin of at least 1cm. The mediastinum lymph nodes were dissected through the trans-esophageal hiatus approach. The surgery lasted 3.5 h and estimated blood lost was 200 mL. The patient was well-recovered and discharged 11 days after surgery (Table 1). Subsequent pathological findings of the hepatic lesion were consistent with those of needle biopsy. The resected tissue was composed of epithelial cells with irregular tubular shapes, exhibiting cytological atypia and collagenous stroma with plasmocytic infiltration (Figure 4A and B). All margins were negative. Again, no neoplastic composition was found in the resected lymph nodes, whereas lymphatic hyperplasia with massive plasmocytic infiltration was observed.
Figure 3

Macroscopic view of surgical specimens. A: Sectional appearance of the hepatic lesion; B: Enlarged mediastinal lymph node (multiple nodes merged). Bar = 1 cm.

Table 1

Timeline of management

Time (day)
Event
1Outpatient evaluation
4Hospitalization
6Found liver mass by CT
11PET-CT
13Core needle biopsy of the liver mass
15Cervical lymph node biopsy
25Surgery
36Discharge

CT: Computed tomography; PET: Positron emission tomography.

Figure 4

Microscopic pathology of surgical specimens. A and B: H & E staining of hepatic lesion, (A) H & E × 100 (B) H & E × 200. The malignant component of a tumor consists of deformed fused glandular ducts that form a sieve, and cord-like structures. The neoplastic cells are of medium size with well-defined nucleoli, and most of the cytoplasm is pale, slightly acidophilic or vacuolated; C and D: Immunohistochemical staining of IgG4 and HHV8 in mediastinal lymph node (× 100). Bar = 100 μm.

Macroscopic view of surgical specimens. A: Sectional appearance of the hepatic lesion; B: Enlarged mediastinal lymph node (multiple nodes merged). Bar = 1 cm. Microscopic pathology of surgical specimens. A and B: H & E staining of hepatic lesion, (A) H & E × 100 (B) H & E × 200. The malignant component of a tumor consists of deformed fused glandular ducts that form a sieve, and cord-like structures. The neoplastic cells are of medium size with well-defined nucleoli, and most of the cytoplasm is pale, slightly acidophilic or vacuolated; C and D: Immunohistochemical staining of IgG4 and HHV8 in mediastinal lymph node (× 100). Bar = 100 μm. Timeline of management CT: Computed tomography; PET: Positron emission tomography. Immunohistochemical staining was positive for CD3, CD20, CD10, CD21, KappaK, Lambda, and IgG4 (Figure 4C) but negative for HHV8 (Figure 4D). For the differential diagnosis of immune-mediated diseases such as IgG4-related lymphadenopathy, the patient’s serum IgG4, IgE, and IL-6 levels were tested, all within normal ranges.

OUTCOME AND FOLLOW-UP

The patient did not develop recurrence of the hepatic lesion during the 12 mo postoperative follow-up (assessed by local CT); no fever, epigastric pain, or other discomfort was present.

DISCUSSION

BAF is a rare primary hepatic tumor first described in 1993 by Tsui et al[1]. It is pathologically characterized by dilated ductular structures lined with bland cuboidal epithelial cells and an abundant fibroblastic stroma. BAFs are generally regarded as benign lesions, but they should be considered premalignant neoplasms because of their potential for malignant transformation[2,6]. The literature has limited reports of BAFs with malignant features, with only 13 cases to date (Table 2). Based on a recent review[7], the malignant transformation was found in 37% (7/19) of BAF cases that underwent resection. Three cases were reported as cholangiocarcinoma arising from BAFs, 2 cases as adenocarcinomas, and 1 unspecified carcinoma, while the others contained some microscopic malignant features such as dysplastic changes and microinvasion. BAF has been reported to arise from liver cirrhosis secondary to chronic hepatitis C virus infection[7]. Immunohistochemistry (IHC) revealed that the epithelial component of the BAF was positive for CK7 and CK19. Of the 5 cases, 3 were positive for p53 on IHC staining. The Ki-67 index ranged from 2% to 50% in 6 cases with available data. Wide local resection is recommended as the primary treatment for BAFs with malignant transformation, and follow-up imaging is needed for potential recurrence[2]. Only 2 of the reported patients developed recurrence after surgery, presenting as local hepatic recurrence, and 1 with pulmonary metastasis[8,9], whereas other cases, with follow-up data from 1 mo to 9 years, had no postoperative recurrence. Therefore, despite the heterogeneity of the pathological features in these cases, BAFs with malignant transformation generally have a good prognosis after complete resection.
Table 2

Biliary adenofibroma with malignant transformation of the liver, review of the literature

No.
Ref.
Age
Sex
Tumor location
Size (cm)
Treatment
Ki67, %
p53
Outcome
Additional information
1Akin et al[8], 200225MRight hepatic lobe20Right hepatectomyNANAHepatic recurrence and pulmonary metastasis after 3 yr
2Kai et al[12], 201240MRight hepatic lobe7Right hepatectomy5-10NANo recurrence at 8-mo follow-up
3Nguyen et al[13], 201253FSegment IVb6.5Resection of segments III/IVNANANo recurrence after 12 mo
4Tsutsui et al[5], 201469FSegment VI3.5Partial hepatectomy10-15Focally positiveNo recurrence at 4-yr follow-upDysplastic changes
5Thompson et al[4], 201671MLeft hepatic lobe14.5Left hepatectomy NANANo recurrence of liver tumor for 9 yrModeratlely-differentiated adenocarcinoma
6Thompson et al[4], 201671MCaudate lobe6.3Codate lobectomyNANANo recurrence at 1-mo follow-upWell-differentiated adenocarcinoma
7Godambe et al[6], 201671FSegments II, III and IVa5.7Left hepatectomy 50PositiveNAMicroinvasive carcinoma
8Thai et al[14], 201677MSegment II4Left hepatectomy NANANACholangiocarcinoma arising from BAF
9Kaminsky et al[2], 201737FSegment V4.5Partial hepatectomy50NegativeNo recurrence at 4-mo follow-upCholangiocarcinoma arising from BAF
10Chua et al[7], 201866FSegment IVb6Wedge resection 2PositiveNo recurrence at 4-mo follow-upCholangiocarcinoma arising from BAF
11Sturm et al[15], 201963FSegment IVa6.3Left hepatectomy20-30Focally positiveNo recurrence at 24-mo follow-up
12Alshbib et al[9], 202263MSegments IVb and V15.5Resection of segments IVb and V25WeakHepatic recurrence 3 mo
13Current report51FSegments VII and VIII7.5Partial hepatectomy5NegativeNo recurrence at 12-mo follow-up

BAF: Biliary adenofibroma; NA: Not available.

Biliary adenofibroma with malignant transformation of the liver, review of the literature BAF: Biliary adenofibroma; NA: Not available. In the current case, the multiple enlarged lymph nodes were first misinterpreted as metastases arising from the hepatic neoplasm, leading to an initial diagnosis of advanced liver malignancy and, correspondingly, a plan for systemic treatment such as chemotherapy or targeted therapy. For advanced disease with high suspicion of hepatocellular carcinoma, pathology is not mandatory prior to systemic treatment. In this case, the imaging studies did not suggest a definite diagnosis, therefore, a core needle biopsy was conducted after prudent evaluation. Finally, the pathological diagnosis was BAF with malignant transformation, thus providing a rationale for complete resection of the neoplasm. Lymphadenopathy showed no evidence of malignancy. It was first suspected to be IgG4-related or multicentric Castleman’s disease due to its histology and positive IHC staining for IgG4[10,11]. However, the patient’s serum IgG4, IgE, and IL-6 levels were within the normal range; therefore, we did not reach a definite diagnosis for her lymphadenopathy. The patient’s fever was non-specific, which could be interpreted as an infection or neoplastic fever, apart from immune-mediated diseases. Notably, the fever did not recur, and CRP and erythrocyte sedimentation rates were normal after surgery. The limitation of this case is that, despite exclusive diagnosis for IgG4-related or multicentric Castleman’s disease, we eventually did not reach a diagnosis for the patient’s lymphadenopathy. Besides, we did not conduct molecular analysis such as MSI state and PD-L1 expression of the BAF sample. Additional molecular analysis may assist follow-up treatment of this disease in case of recurrence.

CONCLUSION

In summary, BAFs with malignant transformation are clinically unusual and could be misinterpreted as liver carcinoma based on imaging features, especially when comorbid with other suspicious signs of malignancy, such as lymphadenopathy. Our case serves as an example of a rare manifestation of BAF, a biopsy of suspicious lesions is vital for diagnosis. According to previous reports, BAFs with malignant transformation have the potential to develop into intrahepatic cholangiocarcinoma or adenocarcinoma, curative resection should be considered an essential primary treatment, which generally leads to a favorable outcome.
  15 in total

1.  Biliary adenofibroma with malignant transformation and pulmonary metastases: CT findings.

Authors:  Oguz Akin; Mehmet Coskun
Journal:  AJR Am J Roentgenol       Date:  2002-07       Impact factor: 3.959

2.  A case of unclassified multicystic biliary tumor with biliary adenofibroma features.

Authors:  Keita Kai; Tomomi Yakabe; Naohiko Kohya; Atsushi Miyoshi; Shinji Iwane; Toshihiko Mizuta; Kohji Miyazaki; Osamu Tokunaga
Journal:  Pathol Int       Date:  2012-05-10       Impact factor: 2.534

3.  Biliary Adenofibroma of Liver: Morphology, Tumor Genetics, and Outcomes in 6 Cases.

Authors:  Thomas Arnason; Darrell R Borger; Christopher Corless; Catherine Hagen; A John Iafrate; Hala Makhlouf; Joseph Misdraji; Heidi Sapp; Wilson M Tsui; Ian R Wanless; Tania Zuluaga Toro; Gregory Y Lauwers
Journal:  Am J Surg Pathol       Date:  2017-04       Impact factor: 6.394

4.  Clinical characteristics of a concurrent condition of IgG4-RD and Castleman's disease.

Authors:  Xia Zhang; Panpan Zhang; Linyi Peng; Yunyun Fei; Wei Zhang; Ruie Feng; Wen Zhang
Journal:  Clin Rheumatol       Date:  2018-06-14       Impact factor: 2.980

5.  Biliary adenofibroma: A rare hepatic lesion with malignant features.

Authors:  Paul Kaminsky; Joshua Preiss; Eizaburo Sasatomi; David A Gerber
Journal:  Hepatology       Date:  2016-11-05       Impact factor: 17.425

6.  Biliary adenofibroma with ominous features of imminent malignant changes.

Authors:  Akemi Tsutsui; Yoshimi Bando; Yasunori Sato; Hidenori Miyake; Seiko Sawada-Kitamura; Hiroshi Shibata; Yuko Kakuda; Kenichi Harada; Motoko Sasaki; Yasuni Nakanuma
Journal:  Clin J Gastroenterol       Date:  2014-08-20

7.  A case of biliary adenofibroma with malignant transformation.

Authors:  Elena Thai; Raffaele Dalla Valle; Francesco Evaristi; Enrico Maria Silini
Journal:  Pathol Res Pract       Date:  2015-12-31       Impact factor: 3.250

8.  Biliary adenofibroma with carcinoma in situ: a rare case report.

Authors:  N Thao T Nguyen; Theresa R Harring; Laurie Holley; John A Goss; Christine A O'Mahony
Journal:  Case Reports Hepatol       Date:  2012-09-03

9.  A case of biliary adenofibroma of the liver with malignant transformation: a morphomolecular case report and review of the literature.

Authors:  Anne-Kathrin Sturm; Thilo Welsch; Christoph Meissner; Daniela E Aust; Gustavo Baretton
Journal:  Surg Case Rep       Date:  2019-06-24

10.  Biliary Adenofibroma: A Rare Liver Tumor with Transition to Invasive Carcinoma.

Authors:  Ayham Alshbib; Krzysztof Grzyb; Trygve Syversveen; Henrik Mikael Reims; Kristoffer Lassen; Sheraz Yaqub
Journal:  Case Rep Surg       Date:  2022-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.